【炎症領域事業本部】Therapeutic Specialist（IBD・神奈川） at Gilead Sciences

Tokyo, Japan

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, HealthcareIndustries

Requirements

患者を助ける先進治療における最高の製品になるという強い意思
IBD領域もしくは生物学的製剤・JAKの経験者
PIPプログラムに参加したことがないこと、または参加していないこと
MR資格保有者
Nice to have:
パートナービジネス（コ・プロモーション）の経験がある
自分の意見や提案を出し、率先して実行できる（積極性）
目標を達成し、やり遂げるために、困難な問題や今までやったことのないことにも積極的に取り組む能力がある（チャレンジ精神・粘り強さ）

Responsibilities

販売計画の達成
医療従事者の製品特性やポジショニングの理解向上
各種KPIの遂行（計画通りの訪問、医師とのコミュニケーション、パートナーとのコミュニケーション）
事業本部への貢献：獲得した知識の共有、チームとの知識・経験の共有、提案活動
独自またはマーケティング部門と連携したイベントの実施
医療従事者のインサイト、市場動向等の情報収集

Skills

IBD

JAK阻害剤

潰瘍性大腸炎

MR資格

営業

プロモーション

KPI管理

医療従事者対応

市場インサイト

チーム連携

Gilead Sciences

Develops and commercializes biopharmaceuticals

About Gilead Sciences

Gilead Sciences focuses on discovering, developing, and commercializing medicines for various medical conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company conducts extensive research and development to create new therapies, which are then marketed to healthcare providers, hospitals, and pharmacies after receiving regulatory approval. Gilead differentiates itself from competitors through its strong commitment to R&D and strategic partnerships, such as with SAP Ariba, to enhance its operations and product offerings. The company's goal is to improve health equity and access to care globally, working with communities to ensure that its medicines reach those in need.

Foster City, CaliforniaHeadquarters

1987Year Founded

$15,873.6MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Risks

Increased competition in HIV treatment from ViiV Healthcare's expanding drug portfolio.

Regulatory scrutiny over drug pricing could impact Gilead's U.S. market operations.

Patent expirations, like Truvada's, lead to increased generic competition and revenue loss.

Differentiation

Gilead's lenacapavir is recognized as the 2024 Breakthrough of the Year for HIV care.

Partnerships with LEO Pharma and Tubulis enhance Gilead's focus on inflammatory and cancer therapies.

Gilead's commitment to health equity initiatives like COMPASS and HepConnect sets it apart.

Upsides

Gilead's strategic partnerships expand its reach in inflammatory and oncology drug markets.

Investment in digital health technologies enhances Gilead's R&D and patient engagement.

Focus on sustainability improves Gilead's operational efficiency and corporate reputation.

Land your dream remote job 3x faster with AI

Try Jobo Free